Consensus guidelines: Preconception counseling, management, and care of the pregnant woman with epilepsy

Neurology

Volumn 42, Issue 4, 1992, Pages 149-160

  Delgado Escueta, Antonio V ^a   Janz, Dieter ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; FOLIC ACID;

CHILD DEVELOPMENT; CONFERENCE PAPER; CONGENITAL MALFORMATION; COUNSELING; DELIVERY; DRUG EFFECT; EPILEPSY; FEMALE; FETUS; GROWTH; HUMAN; IATROGENIC DISEASE; INTRAUTERINE GROWTH RETARDATION; LABOR; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL CARE; PRENATAL DIAGNOSIS; PRESCHOOL CHILD; PUERPERIUM;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; CHILD DEVELOPMENT; CHILD, PRESCHOOL; COUNSELING; DELIVERY, OBSTETRIC; EPILEPSY; FEMALE; FETAL GROWTH RETARDATION; FETUS; FOLIC ACID; GROWTH; HUMAN; LABOR, OBSTETRIC; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL CARE; PRENATAL DIAGNOSIS; PUERPERIUM;

EID: 0026840949     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: None     Document Type: Article

References (102)

1. Guidelines for the care of epileptic women of childbearing age. Epilepsia 1989;30:409-410.
2. Hiilesmaa VK. Pregnancy and birth in women with epilepsy. Neurology 1992;42(suppl 5):8-11.
3. Nelson KB, Ellenberg JH. Maternal seizure disorder, outcome of pregnancy, and neurologic abnormalities in the children. Neurology 1982;32:1247-1254.
4. Egenaes J. Outcome of pregnancy in women with epilepsy, Norway 1967-1978: complications during pregnancy and delivery. In: Janz D, Dam M, Richens A, et al, eds. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982:81-85.
5. Yerby M, Koepsell T, Daling J. Pregnancy complications and outcomes in a cohort of women with epilepsy. Epilepsia 1985;26:631-635.
6. Tanganelli P, Regesta G. Epilepsy, pregnancy, and major birth anomalies: an Italian prospective controlled study. Neurology 1992;42(suppl 5):89-93.
7. Schmidt D, Beck-Mannagetta G, Janz D, et al. The effect of pregnancy on the course of epilepsy: a prospective study. In: Janz D, Dam M, Richens A, et al, eds. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982:39-49.
8. Svigos JM. Epilepsy and pregnancy. Aust NZ J Obstet Gynaecol 1984;24:182-185.
9. Sabin M, Oxorn M. Epilepsy and pregnancy. Obstet Gynecol 1956;7:175-179.
10. Hiilesmaa VK, Bardy AH, Teramo K. Obstetric outcome in women with epilepsy. Am J Obstet Gynecol 1985; 152:499-504.
11. Hiilesmaa VK. A prospective study on maternal and fetal outcome in 139 women with epilepsy. Helsinki, Finland: University of Helsinki, 1982:43:55. Dissertation.
12. Janz D, Beck-Mannagetta G. Complications of pregnancy in women with epilepsy: a retrospective study, In: Janz D, Dam M, Richens A, et al, eds. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982:103-108.
13. Martin F. Grossesse et epilepsie. Rev Med Suisse Romande 1978;98:199-209.
14. Dansky L, Wolfson C, Andermann E, et al. A multivariate analysis of risk factors for congenital malformations in offsprings of epileptic women [abstracts Epilepsia 1989;30:678.
15. Nakane Y, Okuma T, Takahashi R, et al. Multi-institutional study on the teratogenicity and fetal toxicity of anticonvulsants: a report of a collaborative study group in Japan. Epilepsia 1980;21:663-680.
16. Granstrom M-L. Development of the children of epileptic mothers: preliminary results from the prospective Helsinki study. In: Janz D, Dam M, Richens A, et al, eds. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982:403-408.
17. Nakane Y. Congenital malformation among infants of epileptic mothers treated during pregnancy. The report of a collaborative study group in Japan. Folia Psychiatr Neurol Jpn 1979;33:363-369.
18. Mastroiacova P, Bertollini R, Licata D, et al. Fetal growth in the offspring of epileptic women: results of an Italian multi- centric cohort study. Acta Neurol Scand 1988;78:110-114.
19. Annegers JF, Elvebeck LR, Hauser WA, et al. Congenital malformations and seizure disorders in the offspring of parents with epilepsy. Int J Epidemiol 1978;7:241-247.
20. Bossi L, Battino D, Caccamo ML, et al. Risk of malformations in newborns of epileptic mothers: updated results of the Milan collaborative study. In: Janz D, Dam M, Richens A, et al, eds. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982:1-9.
21. Dansky LV, Andermann E, Rosenblatt D, et al. Anticonvulsants, folate levels, and pregnancy outcome: a prospective study. Ann Neurol 1987;21:176-182.
22. Gaily E, Kantola-Sorsa E, Granstrom M-L. Intelligence of children of epileptic mothers. J Pediatr 1988;113:677-684.
23. Hiilesmaa VK, Teramo K, Granstrom M-L, et al. Fetal head growth retardation associated with maternal antiepileptic drugs. Lancet 1981;2:165-167.
24. Koch S, Losche G, Jager-Roman E, et al. Major birth malformations and antiepileptic drugs. Neurology 1992;42(suppl 5):83-88.
25. DiLiberti JH, Farndon PA, Dennis NR, et al. The fetal valproate syndrome. Am J Med Genet 1984;19:473-481.
26. Jager-Roman E, Deichl A, Jakob S, et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr 1986;6:997-1004.
27. Robert E, Guibaud P. Maternal valproic acid and congenital neural-tube defects. Lancet 1982;2:937.
28. Andermann E, Andermann F, Dansky LV. Counseling for epileptic women of childbearing age. In: Dam M, Gram L, Penry JK, eds. Advances in epileptology: Xllth Epilepsy International Symposium. New York: Raven Press, 1981:219-227.
29. Lindhout D, Hoppener RJEA, Meinardi H. Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia 1984;25:77-83.
30. Lindhout D, Schmidt D. In utero exposure to valproate and neural-tube defects. Lancet 1986;2:1932.
31. Lindhout D, Meinardi H, Meijer JWA, et al. Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations. Neurology 1992;42(suppl 5):94-110.
32. Lindhout D, Julliette GC, Omtzigt JGC, et al. Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology 1992;42(suppl 5):111-118.
33. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991;324:674-677.
34. Kaneko S, Otani K, Kondo T, et al. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology 1992;42(suppl 5):68-74.
35. Dansky LV, Rosenblatt DS, Andermann E. Mechanisms of teratogenesis: folic acid and antiepileptic therapy. Neurology 1992;42(suppl 5):32-42.
36. Andermann E, Oguni M, Dansky LV, et al. Pregnancy outcome in epileptic women followed prospectively [abstract]. Epilepsia 1990;31:648.
37. Dravet C, Julian C, Legras C, et al. Epilepsy, antiepileptic drugs, and malformation in children of epileptic women: a French prospective cohort study. Neurology 1992;42(suppl 5):75-82.
38. Yerby MS, Leavitt A, Erickson DM, et al. Antiepileptic drugs and the development of congenital anomalies. Neurology 1992;42(suppl 5):132-140.
39. Granstrom M-L, Hiilesmaa VK. Malformations and minor anomalies in the children of epileptic mothers: preliminary results of the prospective Helsinki study. In: Janz D, Dam M, Richens A, et al, eds. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982:303-307.
40. Kallen B. A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurol Scand 1986;73:253-259.
41. Lander CM, Eadie MJ. Antiepileptic drug intake during pregnancy and malformed offspring. Epilepsy Res 1990;7:77-82.
42. Kaneko S, Otani K, Fukushima Y, et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia 1988;29:459-467.
43. Feldman G, Weaver D, Lorrien E. The fetal trimethadione syndrome: report of an additional family and further delineation of their syndrome. Am J Dis Child 1977;131:1389-1392.
44. German J, Kowal A, Ehlers K. Trimethadione and human teratogenesis. Teratology 1970;3:349-361.
45. Zackai E, Mellman W, Neiderer B, et al. The fetal trimethadione syndrome. J Pediatr 1975;87:280-284.
46. Schmidt D. Adverse effects of antiepileptic drugs. New York: Raven Press, 1982.
47. Hanson JW, Buehler BA. Fetal hydantoin syndrome: current status. J Pediatr 1982;101:816-818.
48. Hanson JW, Smith DW. The fetal hydantoin syndrome. J Pediatr 1975;87:285-290.
49. Rudd NL, Freedom RM. A possible primidone embryopathy.J Pediatr 1979;94:835-837.
50. Jones KL, Lacro RV, Johnson KA, et al. Pattern of malformations in the children of women treated with carba- mazepine during pregnancy. N Engl J Med 1989;320:1661-1666.
51. Gaily E, Granstrom M-L. Minor anomalies in children of mothers with epilepsy. Neurology 1992;42(suppl 5):128-131.
52. Gaily E, Granstrom M-L, Hiilesmaa V, et al. Minor anomalies in the offspring of epileptic mothers. J Pediatr 1988;112:520-529.
53. Koch S, Gopfert-Geyer I, Jager-Roman E, et al. Anti- epileptika wahrend der schwangerschaft. Dtsch Med Wochenschr 1983;108:250-257.
54. Granstrom M-L, Gaily E. Psychomotor development in children of mothers with epilepsy. Neurology 1992;42(suppl 5):144-148.
55. Gaily E, Granstrom M-L. A transient retardation of early postnatal growth in drug-exposed children of epileptic mothers. Epilepsy Res 1989;4:147-155.
56. Finnell RH, Buehler BA, Kerr BM, et al. Clinical and experimental studies linking oxidative metabolism to phenytoin- induced teratogenesis. Neurology 1992;42(suppl 5):25-31.
57. Finnell RH, Dansky LV. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiologic and experimental findings spanning three decades. 1. Animal studies. Reprod Toxicology 1991;5:281-299.
58. Dansky LV, Finnell RH. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiologic and experimental findings spanning three decades. 2. Human studies. Reprod Toxicology 1991;5:301-335.
59. Buehler BA, Delimont D, Van Waes M, et al. Prenatal prediction of risk for the fetal hydantoin syndrome. N Engl J Med 1990;322:1567-1572.
60. Vert P, Deblay MF, Andre M. Follow-up study on growth and neurologic development of children born to epileptic mothers. In: Janz D, Dam M, Richens A, et al, eds. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982:433-436.
61. Gaily E. Development and growth in children of epileptic mothers. A prospective controlled study. Helsinki: University of Helsinki, 1990.
62. Gaily EK, Granstrom M-L, Hiilesmaa VK, et al. Head circumference in children of epileptic mothers: contributions of drug exposure and genetic background. Epilepsy Res 1990;5:217-222. Dissertation.
63. Hecht JT, Annegers F, Kurland LT. Epilepsy and clefting disorders: lack of evidence of a family association. Am J Med Genet 1989;33:244-247.
64. Kelly TE, Rein M, Edwards P. Teratogenicity of anticonvulsant drugs. IV. The association of clefting and epilepsy. Am J Med Genet 1984;19:451-458.
65. Dronamraju KR. Epilepsy and cleft lip and palate. Lancet 1970;2:876-877.
66. Friis ML, Broeng-Nielsen B, Sindrup EH, et al. Facial clefts among epileptic patients. Arch Neurol 1981;38:227-229.
67. Friis ML, Holm NV, Sindrup EH, et al. Facial clefts in sibs and children of epileptic patients. Neurology 1986;36:346-350.
68. Klepel H, Freitag G. Spina bifida occulta in epilepsy syndromes. Neurology 1992;42(suppl 5):126-127.
69. Santiago M, Martins F, Sousa Fernandes J, et al. Association epilepsie et pathologie malformative du rachis. Boll Lega It Epil 1988;62/63:281.
70. Schmidt D, Canger R, Avanzini G, et al. Change of seizure frequency in pregnant epileptic women. J Neurol Neurosurg Psychiatry 1983;46:751-755.
71. Bardy AH. Epilepsy and pregnancy. A prospective study of 154 pregnancies of 154 epileptic women. Helsinki, Finland: University of Helsinki, 1982. Dissertation.
72. Chadwick D. The discontinuation of AED therapy. In: Pedley TA, Meldrum BS, eds. Recent advances in epilepsy, vol 2. Edinburgh: Churchill Livingstone, 1985:111-124.
73. Janz D. When should antiepileptic drug treatment be terminated? In: Wolf P, Dam M, Janz D, et al, eds. Advances in epileptology, vol 16. New York: Raven Press, 1987:365-372.
74. Wegner O, Nau H. Alteration of embryonic folate metabolism by valproic acid during organogenesis: implications for mechanism of teratogenesis. Neurology 1992;42(suppl 5):17-24.
75. Billings RE. Decreased hepatic 5,10, methylenetetra-hydro- folate reductase activity in mice after chronic phenytoin treatment. Molecular Pharmacol 1984;25:459-466.
76. Mills JL, Rhoads GG, Simpson JL, et al. NICHHD, NIH neural-tube defects study. The absence of a relation between the periconceptual use of vitamins and neural-tube defects. N Engl J Med 1989;321:430-435.
77. Milunksy A, Jick H, Jick SS, et al. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural-tube defects. JAMA 1989;262:2847-2852.
78. MRC Vitamin Study Research Group (Nicolas Wald). Prevention of neural-tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991;338:131-137.
79. Ogawa Y, Kaneko S, Otani K, et al. Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. Epilepsy Res 1991;8:75-78.
80. Starreveld-Zimmerman AAE, Kolk van der WJ, Elshove J, et al. Teratogenicity of antiepileptic drugs. Clin Neurol Neurosurg 1974;77:81-95.
81. Rosenberg L, Mitchell AA, Parsells JL, et al. Lack of relation of oral clefts to diazepam use during pregnancy. N Engl J Med 1983;309:1282-1285.
82. Hobbins JC. Diagnosis and management of neural-tube defects today. N Engl J Med 1991;324:690-691.
83. Nadel AS, Green JK, Holmes LB, et al. Absence of need for amniocentesis in patients with elevated levels of maternal serum a-fetoprotein and normal ultrasonographic examinations. N Engl J Med 1990;323:557-561.
84. Nau H. Teratogenic valproic acid concentrations infusion by implanted minipumps versus conventional injection regime in the mouse. Toxicol Appl Pharmacol 1985;80:243-250.
85. Chen S-S, Perucca E, Lee J-N, et al. Serum protein binding and free concentration of phenytoin and phenobarbitone in pregnancy. Br J Clin Pharmacol 1982;13:547-552.
86. Nau H, Schmidt-Gollwitzer M, Kuhnz W, et al. Antiepileptic drug disposition, protein binding and estradiol/progesterone serum concentration ratios during pregnancy. In: Porter R, Mattson R, Ward AA Jr, et al, eds. Advances in epileptology: XVth International Symposium. New York: Raven Press, 1984:239-249.
87. Yerby MS, Fried PN, McCormick K, et al. Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding. Epilepsy Res 1990;5:223-228.
88. Yerby M. Problems and management of the pregnant woman with epilepsy. Epilepsia 1987;28(suppl 5):S29-S36.
89. Knight AH, Rhind EG. Epilepsy and pregnancy. A study of 163 pregnancies in 59 patients. Epilepsia 1975;16:99-110.
90. Medeiros YS, Calixto JB. Inhibitory effect of diphenylhydan- toin on myometrium from pregnant women in vitro. A comparative study with nicardipine and trifluoperazine. Pharmacol Res 1990;22:597-603.
91. Bleyer WA, Skinner AL. Fatal neonatal hemorrhage after maternal anticonvulsant therapy. JAMA 1976;235:626-627.
92. Vert P, Deblay MF. Hemorrhagic disorders in infants of epileptic mothers. In: Janz D, Dam M, Richens A, et al, eds. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982:387-390.
93. Mountain KR, Hirsch J, Gallus AS. Neonatal coagulation defect due to anticonvulsant drug treatment in pregnancy. Lancet 1970;1:265-268.
94. Waltl H, Mitterstieler G, Schwingskackl A. Hammorrhegische. diathesa bei einem nengeforenen emer mutter mit antiepilep- tischler therapie. Dtsch Med Wochenschr 1974;99:1315-1317.
95. Kuhnz W, Koch S, Jakob S, et al. Ethosuximide in epileptic women during pregnancy and lactation period. Transplacental transfer, serum concentrations in nursed infants and clinical status. Br J Clin Pharmacol 1984;18:671-677.
96. Kuhnz W, Jager-Roman E, Rating D, et al. Carbamazepine and carbamazepine-10,11-epoxide during pregnancy and postnatal period in epileptic mothers and their nursed infants: pharmacokinetics and clinical effects. Pediatr Pharmacol 1983;3:199-208.
97. Philbert A, Pedersen B, Dam M. Concentration of valproate during pregnancy in the newborn and in breast milk. Acta Neurol Scand 1985;72:460-463.
98. Koup JR, Rose JQ, Cohen ME. Ethosuximide pharmacokinetics in a pregnant patient and her newborn. Epilepsia 1978;19:535-539.
99. Nau H, Rating D, Koch S, et al. Valproic acid and its metabolites. Placental transfer, neonatal pharmacokinetics, transfer via mother’s milk and clinical status in neonates of epileptic mothers. J Pharmacol Exp Ther 1981;279:768-777.
100. Kuhnz W, Koch S, Helge H, et al. Primidone and pheno- barbital during lactation period in epileptic women: total and free drug serum levels in the nursed infants and their effects on neonatal behavior. Dev Pharmacol Ther 1988;11:147-154.
101. Kaneko S, Sato T, Suzuki K. The level of anticonvulsants in breast milk. Br J Pharmacol 1979;7:624-627.
102. Laegrid L, Olegard R, Walstrom J, et al. Teratogenic effects of benzodiazepine use during pregnancy. J Pediatr 1989:114:126-131.